These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 4201225)

  • 41. A reduction of Pseudomonas septicemias in burned patients by the immune process.
    Pierson C; Feller I
    Surg Clin North Am; 1970 Dec; 50(6):1377-83. PubMed ID: 4922825
    [No Abstract]   [Full Text] [Related]  

  • 42. Efficacy of ribosomal preparations from Pseudomonas aeruginosa to protect against intravenous Pseudomonas challenge in mice.
    Smith RL; Wysocki JA; Bruun JN; De Courcy SJ; Blakemore WS; Mudd S
    J Reticuloendothel Soc; 1974 Jan; 15(1):22-30. PubMed ID: 4204145
    [No Abstract]   [Full Text] [Related]  

  • 43. Immunity to Pseudomonas aeruginosa induced by OprF following intestinal immunization.
    Cripps AW; Dunkley ML; Taylor DC; Cousins S; Clancy RL
    Adv Exp Med Biol; 1995; 371B():761-3. PubMed ID: 7502893
    [No Abstract]   [Full Text] [Related]  

  • 44. Immunological considerations in the development of
    Baker SM; McLachlan JB; Morici LA
    Hum Vaccin Immunother; 2020; 16(2):412-418. PubMed ID: 31368828
    [No Abstract]   [Full Text] [Related]  

  • 45. Immunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa.
    Farjah A; Owlia P; Siadat SD; Mousavi SF; Ardestani MS; Mohammadpour HK
    APMIS; 2015 Feb; 123(2):175-83. PubMed ID: 25470757
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis.
    Döring G; Dorner F
    Behring Inst Mitt; 1997 Feb; (98):338-44. PubMed ID: 9382758
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of type-specific and non-type-specific pseudomonas vaccine for treatment of pseudomonas sepsis during granulocytopenia.
    Harvath L; Andersen BR
    Infect Immun; 1976 Apr; 13(4):1139-43. PubMed ID: 819373
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
    Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
    APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients.
    Jones RJ; Roe EA; Gupta JL
    Lancet; 1980 Dec; 2(8207):1263-5. PubMed ID: 6108445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Active and passive immunization in the treatment of experimental burn wound sepsis from Pseudomonas.
    Hines JL; Hines DP; Palmintier CC; Fisher MW; Nance FC
    Am Surg; 1974 Dec; 40(12):723-8. PubMed ID: 4215350
    [No Abstract]   [Full Text] [Related]  

  • 51. [Inhibition of generalization of wound infection in immunized rats].
    Pal'tsyn AA; Grishina IA; Kolokol'chikova EG; Chervonskaia NV; Badikova AK; Popova EP
    Biull Eksp Biol Med; 1994 May; 117(5):545-6. PubMed ID: 9296716
    [No Abstract]   [Full Text] [Related]  

  • 52. Vaccines and immunotherapy against Pseudomonas aeruginosa.
    Döring G; Pier GB
    Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
    von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
    Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects.
    Cripps AW; Peek K; Dunkley M; Vento K; Marjason JK; McIntyre ME; Sizer P; Croft D; Sedlak-Weinstein L
    Infect Immun; 2006 Feb; 74(2):968-74. PubMed ID: 16428742
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of naturally occurring antibodies to mucoid Pseudomonas aeruginosa in cystic fibrosis patients.
    Pier GB
    J Infect Dis; 1996 Feb; 173(2):513-5. PubMed ID: 8568328
    [No Abstract]   [Full Text] [Related]  

  • 56. Immunization with Larrea divaricata Cav. proteins elicits opsonic antibodies against Pseudomonas aeruginosa and induces phagocytic activity of murine macrophages.
    Canale FP; Dávila SDV; Sasso CV; Pellarín NW; Mattar Domínguez MA
    Microb Pathog; 2018 May; 118():257-267. PubMed ID: 29559255
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.
    Matthews-Greer JM; Gilleland HE
    J Infect Dis; 1987 Jun; 155(6):1282-91. PubMed ID: 3033095
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models.
    Yang F; Gu J; Yang L; Gao C; Jing H; Wang Y; Zeng H; Zou Q; Lv F; Zhang J
    Sci Rep; 2017 Jun; 7(1):3957. PubMed ID: 28638106
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship of colonization with Pseudomonas aeruginosa to development of Pseudomonas bacteremia in cancer patients.
    Schimpff SC; Moody M; Young VM
    Antimicrob Agents Chemother (Bethesda); 1970; 10():240-4. PubMed ID: 5000256
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.